Alecta Tjanstepension Omsesidigt Acquires 153,500 Shares of Abbott Laboratories $ABT
Alecta Tjanstepension Omsesidigt increased its stake in Abbott Laboratories by 10.5% during the second quarter, acquiring an additional 153,500 shares. This brings their total holdings to 1,609,200 shares, valued at approximately $145.92 million. Other institutional investors also significantly modified their holdings in Abbott Laboratories, with Vanguard Group Inc. and State Street Corp among those increasing their positions.
Abbott Inks $670M Deal To End Some Preterm Formula Claims
Abbott Laboratories has announced a $670 million settlement to partially resolve ongoing litigation. The lawsuits allege that the company's specialty baby formula caused premature infants to develop a severe intestinal condition. This agreement aims to address a significant portion of the claims against the company.
Abbott agrees to $670 million settlement of infant formula cases
Abbott has reached a $670 million settlement to partially resolve litigation concerning alleged harms from its specialty formulas for preterm infants. The settlement involves around 2,000 claimants and includes dropping an appeal against a $495 million judgment awarded to an Illinois mother. Despite the settlement, Abbott maintains confidence in the safety of its products and still faces claims from thousands more individuals.
Is Cooper Companies (COO) Cheap After Slower Growth Forecasts Raised Valuation Concerns?
Cooper Companies (COO) is considered 5.5% undervalued with a fair value estimate of $80.57, trading at $76.16. The company is expected to see substantial revenue growth from its MyDAY contact lens rollout. However, the stock faces risks from slower MyDAY adoption or weakness in its fertility and Paragard IUD segments, and its P/E ratio of 63x is significantly higher than the industry average of 28x, indicating potential valuation risk.
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?
Abbott Laboratories reported stronger-than-expected Q2 fiscal results and raised its annual profit forecast for 2026, primarily due to strong demand for cancer diagnostics and medical devices. This performance reinforces the importance of Abbott's diversified healthcare portfolio as a key earnings driver, despite ongoing competitive and pricing pressures in continuous glucose monitoring. The company's partnership with Google Health for its Lingo biowearable is highlighted as a strategic move to integrate glucose sensing into AI-enabled health platforms.
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?
Abbott Laboratories (ABT) reported stronger-than-expected fiscal Q2 results in August 2026, raising its annual profit forecast due to strong demand for cancer diagnostics and medical devices. This outperformance reinforces the company's diversified healthcare portfolio as a key driver, despite ongoing risks like competition in continuous glucose monitoring. The article discusses how this beat and upgraded outlook affect ABT's investment narrative, including its partnership with Google Health, and its projected revenue and earnings growth towards a $119.12 fair value.
Abbott to pay $670 million to settle some preterm infant formula cases
Abbott has agreed to pay $670 million to partially settle lawsuits alleging harm from its specialty formulas for preterm infants. The settlement covers about 2,000 claims and includes dropping an appeal against a $495 million judgment. While not admitting liability, Abbott aims to resolve a significant portion of the ongoing litigation, which involves allegations of necrotizing enterocolitis (NEC) linked to its products.
Abbott to Pay $670 Million to Settle Baby-Formula Litigation
Abbott has agreed to pay $670 million to settle a lawsuit and approximately 2,000 related claims concerning its specialty formulas for premature infants. This bulk settlement stems from the Gill lawsuit, where a Missouri jury previously ordered Abbott to pay $495 million for failing to warn about the increased risk of a bowel disease associated with its preterm infant formula. Abbott maintains the agreements are not an admission of liability and stands by the safety of its products.
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies
Abbott Laboratories has agreed to pay $670 million to settle a major lawsuit and other claims alleging its premature infant formula causes necrotizing enterocolitis (NEC). The settlement follows
Abbott agrees to $670 million settlement of infant formula cases
Abbott has agreed to a $670 million settlement with three law firms to resolve legal claims from 2,000 individuals concerning its specialty formulas for preterm infants. This settlement includes a previous case where Abbott was ordered to pay $495 million after a jury found its formula caused necrotizing enterocolitis in an infant. Approximately 1,000 similar lawsuits are pending against Abbott and Mead Johnson regarding their infant formulas, though both companies maintain their products do not cause the condition.
Abbott in $670M settlement for some NEC infant formula claims (ABT:NYSE)
Abbott Laboratories has agreed to a $670 million settlement to resolve approximately 2,000 claims. These claims allege that infants suffered necrotizing enterocolitis (NEC) after consuming the company's Similac premature formula. This settlement addresses a significant number of lawsuits related to the infant formula.
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Abbott has reached agreements with three law firms to resolve the Gill case and claims from approximately 2,000 individuals regarding its specialty formulas for preterm infants, totaling around $670 million. The company maintains that its products are safe and essential, citing support from regulatory bodies and medical professionals who state there is no reliable scientific evidence that these formulas cause necrotizing enterocolitis (NEC). These settlements follow several favorable court rulings for preterm formula manufacturers and are seen by Abbott as a constructive step towards resolving the overall litigation while ensuring continued access to vital nutrition for premature infants.
Abbott agrees to pay ~$670M to resolve Gill case and ~2,000 related preterm formula claims
Abbott has agreed to a settlement of approximately $670 million to resolve the Gill verdict and around 2,000 related preterm infant formula claims. The company maintains that this agreement is a compromise of disputed claims and not an admission of liability, while asserting the safety of its products. Despite this settlement, approximately 1,700 lawsuits involving 12,700 individual infants are still pending.
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Abbott has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals related to its specialty formulas for preterm infants, totaling about $670 million. The company maintains that its products are safe and necessary, citing medical and regulatory support, and emphasizes that these agreements are a compromise of disputed claims, not an admission of liability. Abbott continues to address remaining lawsuits while asserting the scientific basis for its products' safety and the critical role they play in neonatal care.
Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims
Abbott Laboratories has agreed to a $670 million settlement to resolve approximately 2,000 lawsuits. These lawsuits alleged that the company's infant formula for premature babies caused necrotizing enterocolitis (NEC), a deadly bowel disease. Abbott maintains it is not admitting liability, and about 1,700 additional lawsuits remain pending.
Stryker (SYK) Secured A $100 Million Contract, Is The Upside Already Priced In?
Stryker (SYK) recently secured a US$100 million contract modification from the US Defense Logistics Agency, which boosted its stock by around 2.7%. While Simply Wall St's narrative valuation suggests the stock is 12.1% undervalued at $386.80, a P/E ratio analysis indicates investors are already paying a premium compared to the industry and peers. The article advises investors to carefully weigh both the potential upsides and risks before making investment decisions, given the mixed signals on its valuation.
Abbott settles Missouri baby formula lawsuit after near $500M verdict
Abbott has settled a baby formula lawsuit in Missouri after a jury had previously awarded a near $500 million verdict. The lawsuit concerned issues related to baby formula, though specific details of the settlement were not immediately available. This resolution follows significant legal proceedings for the company.
MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
MiniMed Group, Inc. has announced the commercial shipment of its MiniMed Flex system in the United States, now featuring Abbott Laboratories' Instinct sensor. This integration combines MiniMed's app-controlled insulin pump with a sensor offering up to 15 days of wear, providing a more discreet and hands-free approach to diabetes management. The move is expected to support MiniMed's growth prospects and strengthen its competitive position in the insulin pump market.
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst
The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, driven by an aging population, increased disease prevalence, and advancements in minimally invasive procedures and remote monitoring. Key trends include the adoption of leadless pacemakers, pulsed field ablation, and AI-enabled cardiac monitoring solutions. Major players like Abbott, Boston Scientific, and Medtronic dominate the market, while innovators introduce next-generation implantable and bioresorbable devices.
Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT
Mirae Asset Global Investments Co. Ltd. significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 38% in the second quarter, adding 522,279 shares to now own 1.90 million shares valued at approximately $172 million. The healthcare product maker reported strong Q2 earnings, beating analyst estimates with $1.31 EPS on $12.59 billion in revenue, and saw a 13% year-over-year revenue increase. Analysts maintain a "Moderate Buy" consensus rating for ABT, with an average price target of $118.67, and the company offers a quarterly dividend of $0.63 per share.
Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT
Murphy Pohlad Asset Management LLC significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 398.6% in the second quarter, purchasing an additional 12,140 shares. Several other institutional investors also adjusted their positions in the healthcare product maker. Abbott Laboratories reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.63 per share.
Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT
Citizens National Bank Trust Department significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 77.3% in the second quarter, now holding 25,885 shares valued at $2.349 million. This move is part of a broader trend, with other institutional investors also modifying their holdings in the healthcare product maker. The article details recent financial performance, dividend announcements, and various analyst ratings for Abbott Laboratories.
Jefferies sets strong price target on upstart cancer stock
Jefferies has initiated coverage on Freenome (FRNM), a cancer-screening company, with a "Buy" rating and a $17 price target, suggesting a significant upside. The bullish outlook is based on Freenome's transition from a research company to a commercial-stage entity, its partnerships with Abbott and Roche, and its pipeline of cancer screening tests beyond its initial colorectal cancer product. While the stock offers high-risk, high-reward potential, investors are advised to wait for sales data from the upcoming fall launch and keep positions small due to the company's early stage and unprofitability.
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting® 2026
Monopar Therapeutics Inc. has announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. Dr. Kent will lead medical affairs as the company prepares for potential FDA approval of ALXN1840, a treatment for Wilson disease. Additionally, two abstracts on ALXN1840 have been accepted for presentation at AASLD - The Liver Meeting® 2026, highlighting the drug's potential and the ongoing unmet need in Wilson disease treatment.
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch
Abbott Laboratories (ABT) is gaining investor attention following the commercial launch of MiniMed's app-controlled MiniMed Flex insulin pump, which integrates Abbott’s Instinct continuous glucose sensor. Despite recent positive stock momentum and an estimated 5.4% undervaluation, the article highlights the importance of considering ongoing pricing pressure in diagnostics and potential impacts from tariffs or foreign exchange on margins. Investors are encouraged to review detailed analysis and risks before making investment decisions.
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability
Amid rising bankruptcy filings and recession warnings, this article identifies three dividend-focused healthcare stocks for investors seeking stability: Abbott Laboratories (ABT), Elevance Health (ELV), and UnitedHealth Group (UNH). These companies offer defensive traits, recurring revenues, and established dividend records, making them potential candidates for portfolios looking for steadier ground in a volatile market. The article details each company's business model, revenue streams, and factors influencing their dividend profiles and financial stability.
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch
Abbott Laboratories (ABT) is considered 5.4% undervalued, trading at $112.68 against a fair value estimate of $119.13. This comes amidst renewed investor interest following MiniMed's U.S. launch of its app-controlled Flex insulin pump, integrating Abbott’s Instinct continuous glucose sensor. Analysts project ABT's earnings to reach $9.5 billion by July 2029, up from $5.4 billion today, but warn of potential headwinds from pricing pressure in diagnostics and foreign exchange fluctuations.
Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices.
Abbott Laboratories reported a strong Q2 2026 with a 4.8% sales increase and a 100 basis point rise in adjusted gross margin, driven by its acquisition of Exact Sciences, innovative electrophysiology solutions, and a rebound in its nutrition segment. Despite a valuation-driven downgrade from "Strong Buy" to "Buy," the company is expected to deliver low-teens annual total returns. Abbott maintains its position as a diversified healthcare leader with positive momentum across key business areas.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Abbott Laboratories' Medical Devices segment is a primary growth driver, fueled by advancements in electrophysiology, increasing adoption of cardiovascular technologies, and the long-term potential of continuous glucose monitoring (CGM). The company is launching new products like the Volt PFA catheter and Libre Duo for glucose and ketone monitoring, and has a strong cardiovascular pipeline extending to 2029 and beyond. Despite this, Abbott's stock has underperformed the industry and currently trades at a higher valuation.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Abbott Laboratories' Medical Devices segment is a key growth driver, propelled by advancements in electrophysiology, widespread adoption of cardiovascular technologies, and the significant long-term potential of continuous glucose monitoring (CGM). The company is launching next-generation products like the Volt PFA catheter and Libre Duo, while also developing a robust cardiovascular pipeline extending into 2029 and beyond. Despite these growth catalysts, ABT shares have declined in the past year, and the stock trades at a higher Price-to-Sales multiple compared to the industry median.
Monopar appoints medical affairs head, presents at liver meeting By Investing.com
Monopar Therapeutics Inc. announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. Dr. Kent brings extensive biopharmaceutical experience to the role. Additionally, Monopar will present two abstracts on its late-stage candidate ALXN1840 for Wilson disease treatment at The Liver Meeting 2026, with one selected for oral presentation and the other for poster presentation.
The Smartest Dividend ETF to Buy With $500 Right Now
The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as a smart investment for consistent, higher-yielding dividends, outperforming the S&P 500 this year. It tracks the Dow Jones U.S. Dividend 100 index, holding high-quality companies like Coca-Cola and Abbott Laboratories, which are Dividend Kings. A $500 investment in SCHD, yielding 3.1%, would buy approximately 14.48 shares.
The Smartest Dividend ETF to Buy With $500 Right Now
The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as a smart investment for consistent, high-yielding dividends. It tracks the Dow Jones U.S. Dividend 100 index, holding companies like Coca-Cola and Abbott Laboratories, both Dividend Kings. SCHD has significantly outperformed the S&P 500 this year, climbing 25.8% compared to the index's 13.7%.
Abbott Laboratories raises earnings outlook after strong Q2, with 37% upside potential.
Abbott Laboratories reported strong Q2 results, exceeding earnings expectations and increasing its full-year guidance. The company projects a 10.4% CAGR over six years, partly due to its acquisition of Exact Sciences, and analysts see a 37% upside potential to a $151 price target. Despite potential risks in its Nutrition segment and regulatory challenges, its strong credit rating and dividend history support a premium valuation.
Live Oak Private Wealth LLC Has $6.07 Million Stock Position in Abbott Laboratories $ABT
Live Oak Private Wealth LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 12.8% in Q2, but still holds 66,922 shares valued at $6.07 million. Despite this, other institutional investors have increased their positions, and 75.18% of the company's stock is owned by institutional investors and hedge funds. Analysts generally maintain a "Moderate Buy" rating for Abbott Laboratories, with a consensus price target of $118.67.
IFP Advisors Inc Purchases 176,649 Shares of Abbott Laboratories $ABT
IFP Advisors Inc significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 307.1% in the second quarter, acquiring an additional 176,649 shares. This brings their total holdings to 234,173 shares, valued at approximately $21.25 million. Abbott Laboratories has a "Moderate Buy" consensus rating from analysts, with an average price target of $118.67, and reported strong quarterly earnings of $1.31 per share on $12.59 billion in revenue, exceeding estimates.
Thomasville National Bank Acquires Shares of 19,194 Abbott Laboratories $ABT
Thomasville National Bank has acquired a new position of 19,194 shares in Abbott Laboratories (NYSE:ABT) during the second quarter, valued at approximately $1.74 million. Other institutional investors also adjusted their holdings in ABT, and the company recently reported quarterly earnings that beat analyst expectations. Abbott Laboratories also declared a quarterly dividend of $0.63 per share.
Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 32,710 Shares
AbbVie (NYSE:ABBV) Executive Vice President Nicholas Donoghoe sold 32,710 shares of the company's stock for approximately $8.18 million, reducing his stake by 30.53%. This sale occurred after AbbVie reported strong quarterly earnings, beating revenue and EPS estimates, and provided positive Q3 2026 guidance. The stock currently holds a "Moderate Buy" consensus rating with an average analyst price target of $275.73 and offers a quarterly dividend of $1.73 per share.
Allied Investment Advisors LLC Buys 17,762 Shares of Abbott Laboratories $ABT
Allied Investment Advisors LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 16.9% in the second quarter, acquiring an additional 17,762 shares and bringing its total holdings to 123,081 shares valued at $11.168 million. Other hedge funds also adjusted their positions in ABT. Analysts have set various price targets and ratings for the stock, with a consensus "Moderate Buy" rating and a target price of $118.67.
Smith & Nephew shares slip on CFO's departure
Smith & Nephew's shares declined by approximately 3% following the announcement that Chief Financial Officer John Rogers will depart the company at the end of September. Rogers will remain in his role until then but has stepped down from the board with immediate effect. Pierre Palassian, senior vice president of finance and group controller, will serve as interim CFO while the company searches for a permanent replacement.
Smith & Nephew drops 3.5% as finance chief quits
Smith & Nephew PLC shares fell by 3.5% after its finance chief, John Rogers, announced his immediate departure from the board to take a new position in the US, with his official exit as CFO scheduled for September 30. Rogers' departure follows three years at the company, during which he contributed to improving financial performance and developing the RISE strategy. Pierre Palassian will serve as interim chief financial officer while the company searches for a permanent replacement.
Smith & Nephew CFO John Rogers To Step Down In September
Smith & Nephew announced that CFO John Rogers will step down from his position on September 30, 2026, to pursue an external opportunity in the US. Pierre Palassian, Senior Vice President Finance and Group Controller, will serve as interim CFO while the company searches for a permanent successor. CEO Deepak Nath thanked Rogers for his contributions to the company's financial performance and strategic development.
REG - Smith & Nephew Plc - Directorate change
Smith+Nephew announced that its Chief Financial Officer, John Rogers, will resign on September 30, 2026, to take an external position in the US. Pierre Palassian, Senior Vice President Finance and Group Controller, will serve as interim CFO while the company searches for a successor. Rogers will not receive a severance payment, and his outstanding incentive awards will be treated in accordance with rules for ordinary leavers.
Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories (ABT) advanced 1.55% to $114.43 on Wednesday, outperforming the broader market. This marked the stock's second consecutive day of gains, in a trading session where the S&P 500 Index and Dow Jones Industrial Average also saw increases.
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains
Abbott Laboratories (ABT) shares rose 2.09% to $112.68 on Tuesday, despite a broader market downturn where the S&P 500 and Dow Jones Industrial Average both fell. Despite its daily gains, the stock underperformed when compared to some competitors. This increase ended a two-day losing streak for the company's stock.
Abbott (ABT) Stock May Be 27% Undervalued As Lingo AI Tie Up Grows
Abbott Laboratories' stock has declined by 13.3% over the past year, but a Discounted Cash Flow (DCF) analysis suggests it may be undervalued by 26.7%. While market-based multiples show the share price is roughly in line with peers and its P/E ratio is similar to the medical equipment industry average, the DCF model points to significant upside. The article highlights mixed valuation signals, suggesting the company's future performance hinges on its ability to convert biowearables and glucose sensor partnerships, like the one with Lingo AI and Google Health, into sustainable cash flows.
Abbott (ABT) Stock May Be 27% Undervalued As Lingo AI Tie Up Grows
Abbott Laboratories' stock has fallen 13.3% over the past year, but its Discounted Cash Flow (DCF) intrinsic value suggests it may be 27% undervalued, trading at around $150.62 per share. While the P/E ratio of 35.4x is above the industry average, a tailored fair P/E of 36.9x indicates it is roughly in line with expectations. The company's partnerships, particularly around glucose sensors and the Lingo AI tie-up with Google Health, are key to its future cash flow potential.
Freenome stock initiated at Buy by TD Cowen on liquid biopsy tech
TD Cowen has initiated coverage on Freenome Inc. (NASDAQ:FRNM) with a Buy rating and a $17.00 price target, citing the company's leading position in liquid biopsy colorectal cancer screening and its differentiated technology. The firm projects significant revenue growth for Freenome, with expectations to reach $107 million in 2026 and $1 billion by 2035. This positive outlook is echoed by other firms like BTIG and Jefferies, which also initiated Buy ratings, highlighting Freenome's potential in multi-cancer early detection and strategic partnerships.
Prevail Innovative Wealth Advisors LLC Invests $2.83 Million in Abbott Laboratories $ABT
Prevail Innovative Wealth Advisors LLC has acquired a new stake of 31,178 shares, valued at approximately $2.83 million, in Abbott Laboratories (NYSE:ABT) during the second quarter. Other institutional investors have also adjusted their holdings in the healthcare product maker. Abbott Laboratories reported strong Q2 earnings, beating analyst estimates with an EPS of $1.31 and a 13% year-over-year revenue increase to $12.59 billion, and maintains a "Moderate Buy" consensus rating from analysts.
Abbott Laboratories $ABT Shares Purchased by Mission Wealth Management LP
Mission Wealth Management LP significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 100.5% in the second quarter, now holding 48,849 shares valued at $4.43 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 75.18%. Analysts have a "Moderate Buy" consensus rating for Abbott, with an average price target of $118.67, despite some recent price target reductions.
